OXYMED is aligned with the clinical protocols and conditions as published by the world leading Sagol Hyperbaric Medicine, Israel and Prof Shai Efrati


 * The Sagol Hyperbaric Centre is the world's largest clinical research facility with over 150 - 200 neurological patients attending daily. 


 ** In excess of 70% of the patients attending the Sagol Center for Hyperbaric Medicine receive HBOT for a range of neurologic conditions including stroke, fibromyalgia, dementia, cognitive decline and other neurodegenerative disorders including brain and organ anti-aging rejuvenation


 *** The Sagol Hyperbaric treatment protocols are very specific to the condition and disorder. Typically patients attend for daily HBOT with the initial treatment period over 3-months ie 60 two hour sessions (120-hours).  The Sagol Center for Hyperbaric Medicine and Research (pdf)


Professor Shai Efrati, MD, is the Director of the Sagol center for hyperbaric medicine and research at Assaf-Harofeh Medical Center in Israel. The center, under Prof. Efrati management, has become the largest most occupied hyperbaric center worldwide, currently treating more than 150 patients per day. Prof. Efrati is also the director of Research & Development of Assaf-Harofeh Medical center, affiliated to Tel-Aviv University. Taking the two passions/positions together Dr. Efrati has initiated a research program focusing on the neuroplasticity (regeneration of brain tissue) of Hyperbaric Oxygen Therapy (HBOT). In the first clinical studies, it was proved that HBOT can induce neuroplasticity in post stroke and Traumatic Brain Injury even years after the acute Insult. The important clinical results gained from the research program have led to fruitful cooperation including multidiscipline team focusing on regeneration of injured brain.



Adv Drug Deliv Rev. 2017 Feb 15. pii: S0169-409X(17)30028-5. doi: 10.1016/j.addr.2017.02.001. [Epub ahead of print]

Mimicking Oxygen delivery and waste removal functions of blood.

Zhang H1, Barralet JE2.

Author information


In addition to immunological and wound healing cell and platelet delivery, ion stasis and nutrient supply, blood delivers oxygen to cells and tissues and removes metabolic wastes. For decades researchers have been trying to develop approaches that mimic these two immediately vital functions of blood. Oxygen is crucial for the long-term survival of tissues and cells in vertebrates. Hypoxia (oxygen deficiency) and even at times anoxia (absence of oxygen) can occur during organ preservation, organ and cell transplantation, wound healing, in tumors and engineering of tissues. Different approaches have been developed to deliver oxygen to tissues and cells, including hyperbaric oxygen therapy (HBOT), normobaric hyperoxia therapy (NBOT), using biochemical reactions and electrolysis, employing liquids with high oxygen solubility, administering hemoglobin, myoglobin and red blood cells (RBCs), introducing oxygen-generating agents, using oxygen-carrying microparticles, persufflation, and peritoneal oxygenation. Metabolic waste accumulation is another issue in biological systems when blood flow is insufficient.

Metabolic wastes change the microenvironment of cells and tissues, influence the metabolic activities of cells, and ultimately cause cell death. This review examines advances in blood mimicking systems in the field of biomedical engineering in terms of oxygen delivery and metabolic waste removal.


Hyperbaric Oxygen Therapy in China (2015)

'Currently, there are more than 5000 hyperbaric oxygen chambers in China [4].


  • This number is the highest in the world, and significantly contributes to the amount of global HBOT research [4].

  • In China, HBOT has been adapted to treat a wide variety of diseases. This paper reviewed the current clinical applications of HBOT (including indications and contraindications) and both clinical and basic HBOT research in China in recent years to provide theoretical evidence for a rational clinical use of HBOT.

  • Emergency indications are diseases where HBOT should be administered as soon as possible.

The following are emergency indications:

(1) acute carbon monoxide poisoning and other harmful gas poisoning;

(2) gas gangrene, tetanus and other anaerobic bacteria infections;

(3) decompression sickness;

(4) air embolism syndrome;

(5) after cardiopulmonary resuscitation (CPR) due to a variety of risks for acute brain dysfunction;

(6) aid in the treatment of shock;

(7) brain edema;

(8) pulmonary edema (except cardiac pulmonary edema);

(9) crush syndrome;

(10) limb (finger, toe) and the blood supply after skin transplantation;

(11) drug and chemical poisoning;

(12) acute ischemia anoxic encephalopathy.


  • The current HBOT indications and contraindications were released at the 22nd academic meeting held in Qingdao in 2013 and approved on the 1st of November 2013. The new indications include diseases that were directly or indirectly caused by hypoxia and/or ischemia or a series of conditions that are related to hypoxia and/ or ischemia in the evolution of the disease process.

  • In comparison to the 2004 edition, the new indications broaden the use of HBOT.

Additionally, the following non-emergency indications  approved for use:

(1) carbon monoxide poisoning or other toxic encephalopathy;

(2) sudden deafness;

(3) ischemic cerebrovascular disease (cerebral arteriosclerosis, transient ischemic attack, cerebral thrombosis, cerebral infarction);

(4) craniocerebral injury (concussion, cerebral contusion of intracranial hematoma removal surgery, brain stem injury);

(5) cerebral hemorrhage recovery;

(6) poor healing fractures;

(7) central serous retinal inflammation;

(8) vegetative state;

(9) plateau adaptation insufficiency syndrome;

(10) peripheral nerve injury;

(11) intracranial benign tumor surgery;

(12) periodontal disease;

(13) viral encephalitis;

(14) facial paralysis;

(15) osteomyelitis;

(16) aseptic osteonecrosis;

(17) cerebral palsy;

(18) fetal developmental delays;

(19) diabetes and diabetic foot;

(20) coronary atherosclerotic heart disease (angina and myocardial infarction);

(21) rapidity arrhythmia (atrial fibrillation, premature beat, tachycardia);

(22) myocarditis;

(23) peripheral vascular disease, vasculitis, e.g., Raynaud’s, deep vein thrombosis, etc.;

(24) vertigo;

(25) chronic skin ulcer (arterial blood supply obstacles, venous congestion, bedsore);

(26) spinal cord injury (acute, chronic);

(27) peptic ulcer;

(28) ulcerative colitis;

(29) infectious hepatitis (use the special chamber of infectious disease);

(30) burns;

(31) frostbite;

(32) plastic surgery;

(33) skin grafting;

(34) sports injuries;

(35) radioactive damage (bone and soft tissue, cystitis, etc.);

(36) malignant tumors (with radiotherapy or chemotherapy);

(37) otic nerve injury;

(38) fatigue syndrome;

(39) angioneurotic headache;

(40) pustular;

(41) psoriasis;

(42) pityriasisrosea;

(43) multiple sclerosis;

(44) acute Guillain-Barre syndrome;

(45) recurrent oral ulcer;

(46) paralytic ileus;

(47) bronchial asthma; and

(48) acute respiratory distress syndrome.